Home Genetic Test Accuracy Can Vary
Posted on: Thursday, 20 March 2008, 00:00 CDT
Many companies offer genetic tests directly to U.S. consumers to self-test for cancer, diabetes and other diseases, but an expect says accuracy can vary.
More than two dozen companies market home genetic tests for disease, other genetic traits and ancestry, while some offer whole genome scans.
In an commentary in the Journal of the American Medical Association, Dr. Kenneth Offit, chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center in New York, voices concerns about the scientific accuracy of some of these tests.
They have not yet been validated in forward looking -- prospective -- clinical studies, Offit said in a statement.
The direct-to-consumer aspect of the tests, excludes guidance from healthcare professionals, Offit says.
This raises concerns that patients/individuals may not have the resources to make unbiased decisions regarding whether to proceed with genetic testing, he said.
Offit says once self-ordered test results are relayed, individuals receiving the results may not also receive counseling regarding appropriate medical interventions for prevention and early detection of genetic disorders.
Some states, such as New York, require genetic testing for disease risk must be requested by a licensed healthcare professional and must be performed in an approved clinical laboratory, Offit says.
Source: United Press International
Related Articles
- Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test
- Interleukin Genetics Enters into New Clinical Research Collaboration With Alticor
- New Genetic Muscular Dystrophy Test
- University College London, Moorfields Eye Hospital and Targeted Genetics Initiate Phase I/II Clinical Trial of Gene Therapy for Childhood Blindness
- Ciphergen Engages PrecisionMed, Inc. As Clinical Trial CRO for Ovarian Tumor Triage Test Clinical Trials
- Interleukin Genetics Licenses DNA-Based Weight Management Technology From GeneOb; Algorithm Contributes to Next Genetic Risk Assessment Test for Interleukin
- British Mishap Tests Clinical-Trial Safety
- Seattle Genetics Expands SGN-40 Clinical Program into Chronic Lymphocytic Leukemia
- Findings Reported From the First Study to Link Patients' Genetic Profiles With Their Clinical Outcomes After Cardiac Operations
- Corautus Genetics' Phase IIb GENASIS Clinical Trial Receives Recommendation to Proceed From Data Monitoring Committee
User Comments (0)
RSS Feeds